Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
Status:
Completed
Trial end date:
2017-02-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of supratherapeutic exposures
of ALS-008176 on the QT/ corrected QT interval (QTc) interval in healthy participants (Panel
2).
Phase:
Phase 1
Details
Lead Sponsor:
Alios Biopharma Inc. Janssen Research & Development, LLC
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination